Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Assessing Expression of PD-L1 in Tumor-Associated Macrophages—Reply

Assessing Expression of PD-L1 in Tumor-Associated Macrophages—Reply Letters coronavirus-disease-(-covid-19)-a-practical-how-to-protocol-for-health-care- Jia Zhang, MD and-public-health-professionals Junke Fu, MD, PhD 6. The Lancet Oncology. Safeguarding cancer care in a post-COVID-19 world. Guangjian Zhang, MD, PhD Lancet Oncol. 2020;21(5):603. doi:10.1016/S1470-2045(20)30243-6 Author Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. COMMENT & RESPONSE Corresponding Author: Guangjian Zhang, MD, PhD, Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Assessing Expression of PD-L1 277# W Yanta Rd, Xi’an, Shaanxi, 710061 China (michael8039@163.com). in Tumor-Associated Macrophages Published Online: August 6, 2020. doi:10.1001/jamaoncol.2020.2698 To the Editor We read with interest the article by Jabbour et al Conflict of Interest Disclosures: None reported. regarding their phase 1 trial of pembrolizumab administered 1. Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab concurrently with chemoradiotherapy for locally advanced administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. non–small cell lung cancer (NSCLC). This nonrandomized con- 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.6731 trolled trial highlights that combined treatment for stage III 2. Mok TSK, Wu YL, Kudaba I, et al; KEYNOTE-042 Investigators. NSCLC is safe and tolerable, with promising progression-free Pembrolizumab versus chemotherapy for previously untreated, survival; however, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Assessing Expression of PD-L1 in Tumor-Associated Macrophages—Reply

Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/assessing-expression-of-pd-l1-in-tumor-associated-macrophages-reply-PHLhMpkZzP

References (5)

  • S. Jabbour, A. Berman, R. Decker, Yong Lin, S. Feigenberg, S. Gettinger, C. Aggarwal, C. Langer, C. Simone, J. Bradley, J. Aisner, J. Malhotra (2020)

    Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.

    JAMA oncology

  • S. Dovedi, Amy Adlard, G. Lipowska-Bhalla, Conor McKenna, Sherrie Jones, E. Cheadle, I. Stratford, Edmund Poon, Michelle Morrow, R. Stewart, Hazel Jones, R. Wilkinson, J. Honeychurch, T. Illidge (2014)

    Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

    Cancer research, 74 19

  • Yuting Liu, J. Zugazagoitia, F. Ahmed, B. Henick, S. Gettinger, R. Herbst, K. Schalper, D. Rimm (2019)

    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy

    Clinical Cancer Research, 26

  • M. Reck, D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, Suman Rao, K. Hotta, M. Leiby, G. Lubiniecki, Shentu Yue, Reshma Rangwala, J. Brahmer (2016)

    Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

    The New England journal of medicine, 375 19

  • T. Mok, Yi‐Long Wu, I. Kudaba, D. Kowalski, B. Cho, H. Turna, G. Castro, V. Srimuninnimit, K. Laktionov, I. Bondarenko, K. Kubota, G. Lubiniecki, Jin Zhang, D. Kush, G. Lopes, G. Adamchuk, M. Ahn, A. Alexandru, O. Altundag, A. Alyasova, O. Andrusenko, K. Aoe, A. Araújo, O. Aren, O. Rodriguez, T. Ativitavas, Oscar Avendano, F. Barata, C. Barrios, C. Beato, Per Bergstrom, D. Betticher, L. Bolotina, Michiel Botha, Sayeuri Buddu, C. Caglevic, A. Cardona, H. Castro, F. Senler, Carlos Cerny, A. Česas, G. Chan, Jian-hua Chang, Gongyan Chen, Xi Chen, S. Cheng, Ying Cheng, N. Cherciu, C. Chiu, S. Cicėnas, D. Ciurescu, G. Cohen, Marcos Costa, P. Danchaivijitr, F. Angelis, S. Azevedo, M. Dediu, Ts Deliverski, P. Marchi, Flor Valles, Z. Ding, Boyan Doganov, L. Dreosti, R. Duarte, Regina Edusma-Dy, S. Emelyanov, M. Erman, Yun Fan, L. Fein, Jifeng Feng, D. Fenton, G. Fernandes, C. Ferreira, F. Franke, H. Freitas, Y. Fujisaka, H. Galindo, Christina Galvez, D. Ganea, N. Gil, G. Girotto, E. Goker, T. Goksel, Gonzalo Aubin, Luis Wolff, H. Griph, M. Gumus, Jacqueline Hall, Greg Hart, L. Havel, Jianxing He, Yong He, C. Hernández, V. Hespanhol, T. Hirashima, Chung-man. Ho, A. Horiike, Y. Hosomi, K. Hotta, M. Hou, S. How, T. Hsia, Yi Hu, M. Ichiki, F. Imamura, O. Ivashchuk, Y. Iwamoto, J. Jaal, J. Jassem, Christa Jordaan, R. Juergens, D. Kaen, E. Kalinka‐Warzocha, N. Karaseva, B. Karaszewska, A. Każarnowicz, K. Kasahara, N. Katakami, T. Kato, T. Kawaguchi, J. Kim, K. Kishi, V. Kolek, Marchela Koleva, P. Kolman, L. Koubková, R. Kowalyszyn, D. Kowalski, K. Koynov, D. Ksienski, T. Kurata, G. Kuusk, L. Kuzina, I. Laczó, G. Ladrera, K. Laktionov, G. Landers, S. Lazarev, G. Lerzo, Krzysztof Kmak, Wei Li, C. Liam, Igor Lifirenko, O. Lipatov, Xiaoqing Liu, Zhe Liu, S. Lo, Valeria Lopes, Karla Lopez, Shun Lu, G. Martinengo, L. Mas, M. Matrosova, Rumyana Micheva, Z. Milanova, L. Miron, Tony Mok, M. Molina, S. Murakami, Y. Nakahara, Tien Nguyen, T. Nishimura, A. Ochsenbein, T. Ohira, Ronny Ohman, C. Ong, G. Ostoros, X. Ouyang, E. Ovchinnikova, O. Ozyılkan, L. Petruželka, Xuan Pham, P. Picon, B. Pikó, A. Poltoratsky, Olga Ponomarova, Patrice Popelkova, G. Purkalne, S. Qin, R. Ramlau, Bernardo Rappaport, Felipe Rey, E. Richardet, J. Roubec, P. Ruff, A. Rusyn, H. Saka, J. Salas, Mario Sandoval, L. Santos, T. Sawa, K. Seetalarom, M. Seker, N. Seki, Freddy Seolwane, L. Shepherd, Sergii Shevnya, A. Shimada, Y. Shparyk, I. Sinielnikov, D. Sirbu, O. Smaletz, João Soares, A. Sookprasert, G. Speranza, V. Sriuranpong, Zinaida Stara, W. Su, S. Sugawara, W. Szpak, Kazuhisa Takahashi, N. Takigawa, Hiroshi Tanaka, Jerry Bing, Q. Tang, P. Taranov, H. Tejada, L. Tho, Yoshitaro Torii, Dmytro Trukhyn, M. Turdean, H. Turna, G. Ursol, J. Vaňásek, M. Varela, M. Vallejo, Luis Vera, A. Victorino, T. Vlásek, I. Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih‐Hsin Yang, T. Yokoyama, T. Yokoyama, H. Yoshioka, F. Yumuk, A. Zambrano, J. Zarbá, O. Zarubenkov, Marius Žemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, A. Zippelius (2019)

    Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    The Lancet, 393

Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.2722
Publisher site
See Article on Publisher Site

Abstract

Letters coronavirus-disease-(-covid-19)-a-practical-how-to-protocol-for-health-care- Jia Zhang, MD and-public-health-professionals Junke Fu, MD, PhD 6. The Lancet Oncology. Safeguarding cancer care in a post-COVID-19 world. Guangjian Zhang, MD, PhD Lancet Oncol. 2020;21(5):603. doi:10.1016/S1470-2045(20)30243-6 Author Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. COMMENT & RESPONSE Corresponding Author: Guangjian Zhang, MD, PhD, Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Assessing Expression of PD-L1 277# W Yanta Rd, Xi’an, Shaanxi, 710061 China (michael8039@163.com). in Tumor-Associated Macrophages Published Online: August 6, 2020. doi:10.1001/jamaoncol.2020.2698 To the Editor We read with interest the article by Jabbour et al Conflict of Interest Disclosures: None reported. regarding their phase 1 trial of pembrolizumab administered 1. Jabbour SK, Berman AT, Decker RH, et al. Phase 1 trial of pembrolizumab concurrently with chemoradiotherapy for locally advanced administered concurrently with chemoradiotherapy for locally advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. non–small cell lung cancer (NSCLC). This nonrandomized con- 2020;6(6):848-855. doi:10.1001/jamaoncol.2019.6731 trolled trial highlights that combined treatment for stage III 2. Mok TSK, Wu YL, Kudaba I, et al; KEYNOTE-042 Investigators. NSCLC is safe and tolerable, with promising progression-free Pembrolizumab versus chemotherapy for previously untreated, survival; however,

Journal

JAMA Oncology – American Medical Association

Published: Oct 6, 2020

There are no references for this article.